Loading patent…
AssigneesSengenics Corporation Pte Ltd, Agency for Science, Technology and Research
InventorsJonathan Michael Blackburn, Arif Anwar, Nurul H. Rutt, Anis Larbi, Olivier Nicolas Felix Cexus, Bernett Lee, Jesus Felix Bayta Valenzuela, Christopher Monterola, Victor Tong
Estimating the term…
A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.
A method for manufacturing a kit for determining the health of a subject from a serum/plasma sample extracted from that subject, comprising the steps of:
A composition comprising a panel of antigens for determining the health of a subject, wherein the antigens comprise MAPK13 (HUMAN Mitogen-activated protein kinase kinase kinase 13), CD96 (HUMAN T-cell surface protein tactile), FKBP3 (HUMAN Peptidyl-prolyl cis-trans isomerase), PPM1A (HUMAN Protein phosphatase 1A), PHLDA1 (HUMAN Pleckstrin homology-like domain family A member 1), GLRX3 (HUMAN Glutaredoxin-3), FEN1 (HUMAN Flap endonuclease 1) and AURKA (HUMAN Aurora kinase A), and optionally comprising one or more of UBE2I (HUMAN SUMO-conjugating enzyme UBC9), AAK1 (HUMAN AP2-associated protein kinase 1), YARS (HUMAN Tyrosine-tRNA ligase, cytoplasmic), ASPSCR1 (HUMAN Tether containing UBX domain for GLUT4), CASP10 (HUMAN Caspase-10), FHOD2 (HUMAN formin homology 2 domain), TCL1A (HUMAN T-cell leukemia/lymphoma protein 1A), and MAP4 (HUMAN Microtubule-associated protein 4) wherein the antigens are biotinylated proteins.
Dependencies are inferred from the claim text.